1
|
Russo E, Gaglianone N, Baldassari S, Parodi B, Cafaggi S, Zibana C, Donalisio M, Cagno V, Lembo D, Caviglioli G. Preparation, characterization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles. Colloids Surf B Biointerfaces 2014; 118:117-25. [PMID: 24742953 DOI: 10.1016/j.colsurfb.2014.03.037] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Revised: 02/27/2014] [Accepted: 03/23/2014] [Indexed: 01/05/2023]
Abstract
A new nanoparticulate system for foscarnet delivery was prepared and evaluated. Nanoparticles were obtained by ionotropic gelation of chitosan induced by foscarnet itself, acting as an ionotropic agent in a manner similar to tripolyphosphate anion. A Doehlert design allowed finding the suitable experimental conditions. Nanoparticles were between 200 and 300nm in diameter (around 450nm after redispersion). Nanoparticle size increased after 5h, but no size increase was observed after 48h when nanoparticles were crosslinked with glutaraldehyde. Zeta potential values of noncrosslinked and crosslinked nanoparticles were between 20 and 25mV, while drug loading of noncrosslinked nanoparticles was about 40% w/w (55% w/w for crosslinked nanoparticles). Nanoparticle yield was around 25% w/w. Crosslinked nanoparticles showed a controlled drug release. Foscarnet released from nanoparticles maintained the antiviral activity of the free drug when tested in vitro against lung fibroblasts (HELF) cells infected with HCMV strain AD-169. Moreover, nanoparticles showed no toxicity on non-infected HELF cells. These nanoparticles may represent a delivery system that could improve the therapeutic effect of foscarnet.
Collapse
Affiliation(s)
- E Russo
- Department of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.
| | - N Gaglianone
- Department of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy
| | - S Baldassari
- Department of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy
| | - B Parodi
- Department of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy
| | - S Cafaggi
- Department of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy
| | - C Zibana
- Department of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy
| | - M Donalisio
- Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga Regione Gonzole 10, 10043 Orbassano, TO, Italy
| | - V Cagno
- Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga Regione Gonzole 10, 10043 Orbassano, TO, Italy
| | - D Lembo
- Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga Regione Gonzole 10, 10043 Orbassano, TO, Italy
| | - G Caviglioli
- Department of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy
| |
Collapse
|